James Frates serves as the Chief Financial Officer at Amylyx Pharmaceuticals Inc., a biopharmaceutical company focused on developing treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. In this role, which he assumed in 2021, Frates oversees all financial operations, including strategic planning, investor relations, capital raising, and compliance. He has played a pivotal role in guiding the company through its initial public offering on Nasdaq and subsequent financing efforts, supporting the commercialization of Relyvrio, Amylyx's breakthrough therapy for ALS approved by the FDA in 2022. Prior to joining Amylyx, Frates held senior finance positions at bluebird bio, inc., a gene therapy company, where he advanced from Senior Director of Finance to Vice President of Finance and Treasurer, and ultimately to Chief Financial Officer from 2019 to 2021. During his tenure, he managed complex financial strategies amid clinical and regulatory milestones, including multiple equity offerings that raised over $1 billion to fund pipeline development. His leadership was instrumental in navigating the biotech sector's volatility, earning recognition for robust financial reporting and investor communication. Frates began his career as a Senior Auditor at Deloitte & Touche, gaining foundational expertise in public accounting before progressing through finance roles at Ironwood Pharmaceuticals, where he served as Director of Finance. A Certified Public Accountant, he holds a B.S. in Accounting from Bentley University. Frates is known for his deep industry knowledge, fostering sustainable growth in innovative biotech firms while prioritizing financial discipline and stakeholder value.